Persistent microalbuminuria after treatment with renin-angiotensin axis blockers: causes and results of treatment intensification

Abstract

Aims: The first phase of this study aimed to determine the causes of persistent microalbuminuria after treatment with renin—angiotensin axis (RAA) blocking drugs. In a second phase we tried to determine if strict control of blood pressure and intensive RAA blockade could induce remission or reduction of microalbuminuria in clinical (primary care) practice.

Patients and methods: The study included both diabetic patients and non-diabetic hypertensive patients treated with RAA drugs in the presence of microalbuminuria. 211 patients were recruited (mean age 66.6±11.3 years, 111 men, 117 were diabetic). In the first phase treatment was optimized at standard doses. In the second phase treatment was increased during a three months period to reach a blood pressure (BP) < 130/80 mmHg by adding other antihypertensive treatment and to obtain maximal RAA blockade using long-acting drugs, increased dosage, or adding further medication at night.

Results: Initial mean BP was 141±16/81±11 mmHg. BP control was unsatisfactory (control of systolic blood pressure [SBP] 19.3%; diastolic blood pressure [DBP] 37.6%). Dosage of RAA blocking drugs was inadequate in 21% of patients. Only 27.4% of patients were taking antihypertensive drugs at night. 30.1% of patients took once daily short acting drugs. During the studymean SBP was reduced to 137±13 mmHg (p < .001) and DBP decreased to 79±10 mmHg (p < .001). Control of SBP improved to 24.5% and DBP control went to 44.4%. Mean microalbuminuria decreased from 64.4±47.0 mg/day to 50.1±53.0 mg/day (p < .001) and the prevalence of microalbuminuria was reduced to 59.1%.

Conclusions: Persistent microalbuminuria was associated with poor blood pressure control and inadequate drug dosage. Low frequency of administration of drugs at night and inappropriate once-daily pills intake were frequent. Strict control of blood pressure and intensive RAA blockade significantly reduced the prevalence of microalbuminuria.

Keywords

Arterial hypertension diabetes mellitus microalbuminuria

Get full access to this article

View all access options for this article.

References

Dinneen SF , Gerstein HC The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus: a systematic overview of the literature. Arch Intern Med 1997; 157: 1413-1418.

Adler AI , Stevens RJ , Manley SE , Bilous RW , Cull CA , Holman RR , Ukpds Group. Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 2003; 63: 225-232.

Mogensen CE Microalbuminuria and hypertension with focus on type 1 and type 2 diabetes . J Intern Med 2003; 254: 45-66.

Gerstein HC , Mann JF , Yi Q. , Zinman B. , Dinneen SF , Hoogwerf B. , et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001; 286: 421-426.

Jensen JS , Feldt-Rasmussen B. , Strandgaard S. , Schroll M. , Borch- Johnsen K. Arterial hypertension, microalbuminuria, and risk of ischemic heart disease . Hypertension 2000; 35: 898-903.

Bigazzi R. , Bianchi S. , Baldari D. , Campese VM Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J Hypertens 1998; 16: 1325-1333.

Hillege HL , Fidler V. , Diercks GFH , van Gilst WH , de Zeeuw D. , van Veldhuisen DJ , et al. for the Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population . Circulation 2002; 106: 1777-1782.

Robles NR , Mena C. , Velasco J. , Angulo E. , Garrote T. , Garcia Gallego F. , en representación de los investigadores del estudio MICREX. Riesgo cardiovascular asociado a microalbuminuria en pacientes diabéticos y en pacientes con hipertensión arterial . Med Clin (Barc) 2008 ; 130: 206-209.

The Seventh Report of Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report . JAMA 2003; 289: 2560-2572.

10.

Mancia G. , De Backer G. , Dominiczak A. , Cifkova R. , Fagard R. , Germano G. , et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-1187.

11.

Chan JC , Ko GT , Leung DH , Cheung RC , Cheung MY , So WY , et al. Long-term effects of angiotensin- converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. Kidney Int 2000; 57: 590-600.

12.

Parving HH , Lehnert H. , Brochner-Mortensen J. , Gomis R. , Andersen S. , Arner P. , Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.

13.

Viberti G. , Wheeldon NM , MicroAlbuminuria Reduction with VALsartan (MARVAL) Study Investigators. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 2002; 106: 672-678.

14.

Perkins BA , Ficociello LH , Silva KH , Finkelstein DM , Warram JH , Krolewski AS Regression of microalbuminuria in type 1 diabetes. N Engl J Med 2003; 348: 2285-2293.

15.

Robles NR , Velasco J. , Mena C. , Angulo E. , Garrote T. , en representación de los investigadores del estudio MICREX. Microalbuminuria en pacientes diabéticos y en pacientes con hipertensión arterial: estudio de una cohorte de 979 pacientes. Med Clín (Barc) 2006; 127: 761-764.

16.

Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2003; 26(Suppl.1): S5-S20.

17.

American Diabetes Association. Standards of Medical Care in Diabetes-2007 . Diabetes Care 2007; 30(Suppl. 1): S4-S41.

18.

The Seventh Report of Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report . JAMA 2003; 289: 2560-2572.

19.

Klausen KP , Scharling H. , Jensen G. , Jensen JS New definition of microalbuminuria in hypertensive subjects: association with incident coronary heart disease and death. Hypertension 2005; 46: 33-37

20.

Mogensen CE , Microalbuminuria predicts clinical proteinuria and early mortality in maturity onset diabetes. N Engl J Med 1984; 310: 356-60.

21.

Erley CM , Haefele U. , Heyne N. , Braun N. , Risler T. Microalbuminuria in essential hypertension: reduction by different antihypertensive drugs. Hypertension 1993; 21: 810-815.

22.

Anderson S. , Diamond JR , Karnovsky MJ , Brenner BM Mechanisms underlying transition from acute glomerular injury to late glomerular sclerosis in a rat model of nephrotic syndrome. J Clin Invest 1988; 82: 1757-1768.

23.

Anderson S. , Brenner BM Therapeutic benefit of converting-enzyme inhibition in progressive renal disease. Am J Hypertens 1988; 1(4Pt2): 380S-383S.

24.

Tanaka R. , Kon V. , Yoshioka T. , Ichikawa I. , Fogo A. Angiotensin converting enzyme inhibitor modulates glomerular function and structure by distinct mechanisms. Kidney Int 1994; 45: 537-543.

25.

Ritz E. , Orth S. , Weinreich T. , Wagner J. Systemic hypertension versus intraglomerular hypertension in progression . Kidney Int 1994; 45: 438-442.

26.

Fogo A. , Yoshida Y. , Glick AD , Homma T. , Ichikawa I. Serial micropuncture analysis of glomerular function in two rat models of glomerular sclerosis. J Clin Invest 1988 ; 82: 322-330.

27.

Lax DS , Benstein JA , Tolbert E. , Dworkin LD Effects of salt restriction on renal growth and glomerular injury in rats with remnant kidneys. Kidney Int 1992 ; 41: 1527-1534.

28.

Hsueh WA , Do YS , Anderson PW , Law RE Angiotensin II in cell growth and matrix production. Adv Exp Med Biol 1995; 377: 217-223.

29.

Bonnet F. , Cooper ME , Kawaci H. , Allen TJ , Boner G. , Cao Z. Irbesartan normalises the deficiency in glomerular nephrin expression in a model of diabetes and hypertension. Diabetologia 2001; 44: 874-877.

30.

Esmatjes E. , Fiores L. , Iñigo P. , Lario S. , Ruilope LM , Campistol JM Effect of losartan on TGF-1 and urinary albumin excretion in patients with type 2 diabetes mellitus and microalbuminuria. Nephrol Dial Transplant 2001; 161(Suppl. 1): 90-93.

31.

Böhm M. , Reil JC , Danchin N. , Thoenes M. , Bramlage P. , Volpe M. Association of heart rate with microalbuminuria in cardiovascular risk patients: data from I-SEARCH. J Hypertens 2008; 26: 18-25.

32.

Ibsen H. , Olsen MH , Wachtell K. , Borch-Johnsen K. , Lindholm LH , Mogensen CE , et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 2005; 45:198-202.

33.

Brunner HR , Menard J. , Waeber B. Burnier M. , Biollaz J. , Nussberger J. , et al. Treating the individual hypertensive patient: considerations on dose, sequential monotherapy and drug combinations. J Hypertens 1990; 8: 3-11.

34.

Düssing R.

Angiotensin II-receptor blocker dosages: How high should we go?

Int J Clin Pract 2006; 60: 179-183.

35.

Hermida RC , Ayala DE , Calvo C. Optimal timing for antihypertensive dosing: focus on valsartan. Ther Clin Risk Management 2007; 3: 119-131.

36.

Ohkubo T. , Hozawa A. , Yamaguchi J. , Kikuya M. , Ohmori K. , Michimata M. , et al. Prognostic significance of the nocturnal decline in blood pressure in individuals with and without high 24-h blood pressure: the Ohasama study . J Hypertens 2002; 20: 2183-2189.

37.

Kikuya M. , Ohkubo T. , Asayama K. , Metoki H. , Obara T. , Saito S. , et al. Ambulatory blood pressure and 10-year risk of cardiovascular and noncardiovascular mortality. The Ohasama Study. Hypertension 2005; 45: 240-245.

38.

Hermida RC , Smolensky MH Chronotherapy of hypertension. Curr Opin Nephrol Hypertens 2004; 13: 501-505.

39.

Hermida RC , Ayala DE , Mojón A. , Fernández JR Chronotherapy with nifedipine GITS in hypertensive patients: improved efficacy and safety with bedtime dosing. Am J Hypertens 2008; 21: 948-954.

40.

Hermida RC , Calvo C. , Ayala DE , Fernández JR , Covelo M. , Mojón A. , et al. Treatment of non-dipper hypertension with bedtime administration of valsartan. J Hypertens 2005; 23: 1913-1922.